Biologicals in osteoporosis: Teriparatide and parathyroid hormone in women and men

被引：9

作者：

Devogelaer J.-P. ^{[1
]}

Boutsen Y. ^{[2
]}

Manicourt D.H. ^{[1
]}

机构：

[1] Department of Rheumatology, Université Catholique de Louvain, UCL 5390, St-Luc University Hospital, Brussels 1200

[2] Department of Rheumatology, Université Catholique de Louvain, Clinique Universitaire de Mont-Godinne

来源：

Current Osteoporosis Reports | 2010年 / 8卷 / 3期

关键词：

Alternate therapy; Bisphosphonate; Bone mineral density; Combined therapy; Fractures; Isolated therapy; Males; Markers of bone remodeling; Osteoporosis; Parathyroid hormone; Postmenopausal females; Raloxifene; Strontium ranelate;

D O I：

10.1007/s11914-010-0024-1

中图分类号：

学科分类号：

摘要：

Osteoporosis is characterized by the occurrence of a host of fractures. According to densitometric values, an operational definition for osteoporosis corresponds to a loss of 25% to 30% (-2.5 T-scores) compared with the mean values of bone mineral density of young premenopausal women. For years, research tried to develop drugs to improve the bone mineral density. According to the compounds, antiresorptive agents are able to decrease the fracture rate by about 30% to 70%, and to increase the bone mineral density. However, the agents increasing the most bone mineral density are not necessarily those that influence the most fracture rates. It has been known for years that parathyroid hormone (PTH) administered cyclically is able to increase bone mineral density. Two analogues of PTH have been developed: PTH (1-34) and PTH (1-84). Both of them are able to increase bone mineral density and reduce the rate of vertebral fracture but not of the hip, nor of nonvertebral fractures, the latter at least for PTH (1-84). Their exact place in the armamentarium of therapy of osteoporosis and their best time of administration are not yet definitely settled. New modes of administration (transdermal, intranasal, oral) will probably become available soon. With all the drugs available today and those still in development, it can be hoped that osteoporosis will become a disease of the past. © 2010 Springer Science+Business Media, LLC.

引用

页码：154 / 161

页数：7

共 60 条

[1]

Watts N.B., Cooper C., Lindsay R., Et al., Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk, J Clin Densitom, 7, pp. 255-261, (2004)

[2]

Cummings S.R., Karpf D.B., Harris F., Et al., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs, Am J Med, 112, pp. 281-289, (2002)

[3]

Sarkar S., Mitlak B.H., Wong M., Et al., Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy, J Bone Miner Res, 17, pp. 1-10, (2002)

[4]

Bruyere O., Roux C., Detilleux J., Et al., Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate, J Clin Endocrinol Metab, 92, pp. 3076-3081, (2007)

[5]

Selye H., On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol, Endocrinology, 16, pp. 547-558, (1932)

[6]

Reeve J., Hesp R., Williams D., Et al., Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis, Lancet, 1, pp. 1035-1038, (1976)

[7]

Reeve J., Meunier P.J., Parsons J.A., Et al., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial, Br Med J, 280, pp. 1340-1344, (1980)

[8]

Reeve J., Davis U.M., Hesp R., Et al., Treatment of osteoporosis with human parathyroid hormone and observations on the effects of sodium fluoride therapy, Br Med J, 301, pp. 314-318, (1990)

[9]

Reeve J., Bradbeer J.N., Arlot M., Et al., HPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses, Osteoporosis Int, 1, pp. 162-170, (1991)

[10]

Slovik D.M., Rosenthal D.I., Doppelt S.H., Et al., Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1, 25-dihydroxyvitamin D, J Bone Miner Res, 1, pp. 377-381, (1986)

← 1 2 3 4 5 6 →